Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules: a pilot study

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tongji Hospital
• Treatments: Nivolumab

Criteria

Inclusion Criteria:

• not less than two GGNs on chest CT

• at least one lesion is diagnosed as NSCLC from biopsy pathology

• no contraindication for surgery

• ECOG score of 0 or 1

• no detectable evidence of distant metastasis

Exclusion Criteria:

• medical history of malignancy

• pregnant or breeding period

• severe organ failure (heart, liver, kidney, and lung)

• high risk of cerebral-cardiovascular evens

• infection out of control

• received or receiving chemo- and radiotherapy

• history of severe reaction due to allergy or hypersensitivity

• severe mental disorder

• currently been enrolled in other trials

• autoimmune or chronic inflammatory disease